版本:
中国

BRIEF-EMA recommends approval of three new cancer treatments

Sept 16 European Medicines Agency

* Recommendations for September 2016

* Recommends approval of Eli Lilly and Boehringer Ingelheim's Glyxambi for treatment of type 2 diabetes

* Recommends approval of Pfizer Inc'S palbociclib to treat breast cancer

* Recommends conditional approval of Eli Lilly's olaratumab to treat soft tissue sarcoma

* Recommends approval of Amgen's etelcalcetide to treat secondary hyperparathyroidism in patients with chronic kidney disease

* Recommends conditional approval of Takeda Pharmaceutical Co Ltd's Ninlaro (ixazomib) to treat multiple myeloma Source text: bit.ly/2cvS1be Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐